Cytotherapy
FOR MEMBER ACCESS CLICK HERE
Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT). Coverage encompasses important new therapies emerging from the manipulation of cytokines and cells, as well as bringing readers the very latest developments news and opinion in the fast-moving fi eld of vaccines, cytokine and cellular therapy. A particular emphasis is on the translation of research from the laboratory into clinical practice.
The journal's scope includes research in:
- Stem cell processing and transplantation
- Cancer
- Stem cell plasticity
- Autoimmune diseases
- Immunotherapy
- Congenital disorders
- Novel molecular therapies
- Gene therapy
- Cell-based therapies of malignant and non-malignant blood diseases
Readership and Target Group: Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists, and immunologists and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.
Keywords: Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.
Submission Details: Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt, whether the manuscript is accepted, requires revision, or is rejected. All manuscripts will be published within 5 months from the date of acceptance. Contributors should submit their papers electronically via the author center at Journal’s manuscript central. Manuscript
central is accessible via: http://mc.manuscriptcentral.com/cytotherapy.
Awards: The Cytotherapy Best Paper Award
The Cytotherapy Best Paper Award is for the best overall original paper published in a given volume of Cytotherapy, the official journal of the International Society for Cellular Therapy.
The Award consists of a check for $2500 and a plaque. The award is presented at the gala dinner of each Annual ISCT Meeting. The judging committee is the ISCT Education and Publications Committee.
Judging criterion will include consideration of the paper's quality, the significance of the contribution to the field, the degree to which the science presented is novel, and the applicability of the science presented to improvements in processing or engineering cells for potential therapeutic purposes.
For advertising information, please contact:
Mr Per Sonnerfeldt
Tel: 0046 46 13 76 90
per.sonnerfeldt@informa.com
Tel: +44 (0)207 017 6189
Fax: +44 (0)207 017 6336
Website: www.informahealthcare.com/cytotherapy
